According to a new research report by Precedence Research, The Scar Treatment Market size is forecast to exceed US$ 61.9 billion by 2030 from USD 20.6 billion in 2020 and is expected to grow at the highest CAGR of 10.7% from 2021-2030. The report offers an up-to-date analysis regarding the current market scenario, latest trends, key drivers, potential challenges, profitability graph and the overall market environment.
Download the Sample Pages of this Report for Better Understanding@ https://www.precedenceresearch.com/sample/1303
Crucial factors accountable for market growth are:
- Rising personal disposable income
- Growing concerns among the young population regarding their looks
- Rising prevalence of skin diseases
- Technological advancements in the scar treatment industry
- Growing number of road accidents
- Easy availability of topical scar treatment products as OTC products
- Rising penetration of healthcare units in emerging countries
Scope of the Scar Treatment Market Report
| Report Coverage | Details |
| Market Size in 2020 | US$ 20.6 billion |
| Growth Rate from 2021 to 2030 | CAGR of 10.7% |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Largest Market | North America |
| Segments Covered | Treatment Type, Scar Type, End Use Type, Region |
| Companies Mentioned | Bausch Health Companies, Inc., Candela Corp., Sonoma Pharmaceuticals, Inc., Hologic, Inc., Johnson & Johnson, Quantum, Inc., CCA Industries, Inc., Avita Medical Ltd., Revitol Corp., Scarguard Labs, LLC. |
Regional Snapshots
North America is the dominating scar treatment market owing to the increased prevalence of scars in the region. According to the NCBI, around 100 million patients acquire scars owing to the elective operations and after-trauma operations in the developed nations, annually. It is estimated that around 11 million people have keloid scars and around 4 million people have burns, of which over 70% of the affected population consists of children. Hence, the growing prevalence of scars coupled with improved healthcare access and demand for aesthetic improvement has fostered the growth of the scar treatment market in North America.
Asia Pacific is estimated to be the fastest-growing market owing to the increased prevalence of road accidents. As per the WHO, the maximum road accidents occur in the low and middle income countries due to the lack of better roadways. Moreover, in the nations like India, where the population of youth is higher than any other nation are expected to foster the market growth. The young population concerned about their looks is significantly propelling the demand for the scar treatment products in the region.
Report Highlights
- By treatment type, the laser segment is anticipated to grow at a rapid pace during the forecast period. This is attributable to the growing awareness regarding the laser skin treatment. Moreover, it provides rapid, effective, and painless treatment of scars.
- By scar type, the hypertrophic & keloid is anticipated to be the most opportunistic segment. The growing prevalence of keloid scars especially in the developed regions like North America and Europe, is estimated to boost the segment growth throughout the forecast period.
- By end use, the home-use segment led the global scar treatment market with remarkable revenue share in 2020. The increasing popularity of e-pharmacy and other digital pharmacy platforms coupled with the increased penetration of retail pharmacies across the world has significantly contributed towards the establishment of this segment as a leading segment in the past.
Market Dynamics
Drivers - Rising prevalence of skin diseases among the population is a major factor boosting the demand for the scar treatment products.The excessive exposure to sunlight and pollution may cause skin disease such as photo-aging, psoriasis, sunburns, and vitiligo. These diseases may lead to scars if not treated properly.
Restraints - Lack of awareness regarding scar treatment, low disposable income, and lack of sophisticated healthcare infrastructure in underdeveloped nations are the major restraints that may hamper the market growth.
Opportunities - Most of the cosmetic surgeons and doctors are now suggesting to use silicone based scar treatment products such as gel sheets, as they are very much effective in eliminating scars overtime. Hence, the adoption of silicone based scar treatment products is a trending topic in the market.
Challenges - The high cost of certain treatments like laser treatment for removing scars is a major challenge that restricts the consumers to opt for other alternatives. Technological innovations are to be undertaken to make this treatment cost-effective for the consumers.
Key Players
The major players operating in the scar treatment market are Sonoma Pharmaceuticals, Inc., Bausch Health Companies, Inc., Quantum, Inc., Candela Corp., Hologic, Inc., Johnson & Johnson, Revitol Corp., CCA Industries, Inc., Avita Medical Ltd., Scarguard Labs, LLC.
Segments Covered in the Report
By Treatment Type
- Topical
- Laser
- Surface
- Surgical
- Injectable
By Scar Type
- Acne & Atrophic
- Stretch Marks
- Hypertrophic & Keloid
- Contracture
By End Use
- Dermatology Clinics
- Home-Use
- Hospitals
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Scar Treatment Market, By Treatment
7.1. Scar Treatment Market, by Treatment Type, 2021-2030
7.1.1. Topical
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Laser
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Surface
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. Surgical
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Injectable
7.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Scar Treatment Market, By End Use
8.1. Scar Treatment Market, by End Use, 2021-2030
8.1.1. Dermatology Clinics
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Home-Use
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Hospitals
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Scar Treatment Market, By Scar
9.1. Scar Treatment Market, by Scar, 2021-2030
9.1.1. Acne & Atrophic
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Stretch Marks
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Hypertrophic & Keloid
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Contracture
9.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Scar Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.2. Market Revenue and Forecast, by End Use (2019-2030)
10.1.3. Market Revenue and Forecast, by Scar (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.6.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Scar (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.7.2. Market Revenue and Forecast, by End Use (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.6.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Scar (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.7.2. Market Revenue and Forecast, by End Use (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.6.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Scar (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.7.2. Market Revenue and Forecast, by End Use (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Scar (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.5.3. Market Revenue and Forecast, by Scar (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.4.2. Market Revenue and Forecast, by End Use (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Scar (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.5.2. Market Revenue and Forecast, by End Use (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Scar (2019-2030)
Chapter 11. Company Profiles
11.1. Bausch Health Companies, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Candela Corp.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Sonoma Pharmaceuticals, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Hologic, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Johnson & Johnson
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Quantum, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. CCA Industries, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Avita Medical Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Revitol Corp.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Scarguard Labs, LLC.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1303
About Us
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace &defense, among different ventures present globally.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments